As of 2024-12-13, the Relative Valuation of Nurix Therapeutics Inc (NRIX) is (56.65) USD. This relative valuation is based on P/E multiples. With the latest stock price at 20.56 USD, the upside of Nurix Therapeutics Inc based on Relative Valuation is -375.5%.
The range of the Relative Valuation is (52.36) - (48.57) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 21.0x - 31.3x | 26.2x |
| Forward P/E multiples | 19.0x - 19.4x | 19.2x |
| Fair Price | (52.36) - (48.57) | (56.65) |
| Upside | -354.7% - -336.2% | -375.5% |
| Date | P/E |
| 2024-11-29 | -8.85 |
| 2024-11-27 | -8.50 |
| 2024-11-26 | -8.72 |
| 2024-11-25 | -8.73 |
| 2024-11-22 | -8.83 |
| 2024-11-21 | -8.95 |
| 2024-11-20 | -9.06 |
| 2024-11-19 | -9.12 |
| 2024-11-18 | -8.72 |
| 2024-11-15 | -9.17 |
| 2024-11-14 | -10.75 |
| 2024-11-13 | -10.87 |
| 2024-11-12 | -10.82 |
| 2024-11-11 | -11.26 |
| 2024-11-08 | -10.94 |
| 2024-11-07 | -10.90 |
| 2024-11-06 | -10.81 |
| 2024-11-05 | -10.18 |
| 2024-11-04 | -10.02 |
| 2024-11-01 | -9.79 |
| 2024-10-31 | -9.84 |
| 2024-10-30 | -9.63 |
| 2024-10-29 | -10.09 |
| 2024-10-28 | -10.59 |
| 2024-10-25 | -10.52 |
| 2024-10-24 | -10.10 |
| 2024-10-23 | -9.92 |
| 2024-10-22 | -10.22 |
| 2024-10-21 | -10.20 |
| 2024-10-18 | -10.03 |
| 2024-10-17 | -9.89 |
| 2024-10-16 | -10.33 |
| 2024-10-15 | -9.95 |
| 2024-10-14 | -10.07 |
| 2024-10-11 | -9.46 |
| 2024-10-10 | -8.75 |
| 2024-10-09 | -8.80 |
| 2024-10-08 | -8.81 |
| 2024-10-07 | -8.62 |
| 2024-10-04 | -8.89 |
| 2024-10-03 | -8.67 |
| 2024-10-02 | -8.79 |
| 2024-10-01 | -8.84 |
| 2024-09-30 | -8.99 |
| 2024-09-27 | -9.23 |
| 2024-09-26 | -9.29 |
| 2024-09-25 | -9.42 |
| 2024-09-24 | -9.72 |
| 2024-09-23 | -9.65 |
| 2024-09-20 | -10.26 |